Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 29, 2021 (5 years ago)

Entacapone Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Entacapone Tablets, USP, 200 mg, Rx only, 30 Tablets per unit dose cartons, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152. NDC 0904-6822-04

Affected NDC 0904-6822-04

Compare with the code on your package — it is the most precise check available.

Drug: Entacapone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Entacapone
NDC 00904-6822
200 mg/1 Tablet, Film Coated
Oral
Major Pharmaceuticals Rx
Recalling firm
The Harvard Drug Group
NDC code
0904-6822-04
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0806-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Entacapone recalls

See all
Class II · Moderate risk

Carbidopa

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Ongoing Labeling / mix-up Rising Pharma Holding, Inc. NDC 16571-691-01 D-0029-2026
Class II · Moderate risk

Stalevo (carbidopa, levodopa, and entacapone)

Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

Terminated Chemical / undeclared Novartis Pharmaceuticals Corp. NDC 0078-9407-01 D-336-2014

Other recalls by The Harvard Drug Group

All 2021 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026